


Continuous positive airway pressure therapy in patients with coronary artery disease and obstructive sleep apnea

January 29 2024





Credit: Pixabay/CC0 Public Domain



Obstructive sleep apnea (OSA) is highly common in patients with coronary artery disease (CAD) and it is a strong predictor of subsequent cardiovascular events. However, whether treatment with continuous positive airway pressure (CPAP) can decrease this risk remains controversial.

PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were systematically searched to identify randomized <u>clinical trials</u> reporting cardiovascular events from database inception to February 12, 2022. The research is <u>published</u> in the journal *Cardiovascular Innovations and Applications*.

Four trials with 3,043 participants were included. The median follow-up duration ranged from 3–4.75 years. Compared with usual care alone, CPAP was not associated with decreased MACCE risk (RR 0.96, 95% CI 0.77–1.21, P = 0.75), and the results were consistent regardless of CPAP adherence (\geq 4 hours/night vs.

Citation: Continuous positive airway pressure therapy in patients with coronary artery disease and obstructive sleep apnea (2024, January 29) retrieved 12 May 2024 from <u>https://medicalxpress.com/news/2024-01-positive-airway-pressure-therapy-patients.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.